Is it worth trying to sell the new JAK product? Strong established products with Enbrel (certainly very familiar) and Humira. Any idea how many rep openings there are going to be?
This mentioned on investor conf call w ELT: $11 million in sales 1st qtr 2013, after stocking up wholesale. Not exactly blockbuster status.
Pfizer should have priced it 25% less than current market, then built in double digit price increases once market share established. Typical Pfizer to go all in anal retentive and blow their wad up front, it's Pfgreed!